New drug combo trial offers hope for Tough-to-Treat esophageal cancer
NCT ID NCT07484724
Summary
This study aims to test the safety and early effectiveness of a new combination therapy called JS212 for adults with advanced esophageal cancer that has spread or returned. It will involve about 280 patients who have not received prior drug treatment for their advanced disease. The main goals are to find the right dose, see how well the tumors shrink, and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.